{"nctId":"NCT02187198","briefTitle":"Buprenorphine Treatment for Opioid Dependence","startDateStruct":{"date":"2015-03"},"conditions":["Opioid Dependence"],"count":9,"armGroups":[{"label":"Buprenorphine low dose","type":"EXPERIMENTAL","interventionNames":["Drug: Buprenorphine"]},{"label":"Buprenorphine high dose","type":"EXPERIMENTAL","interventionNames":["Drug: Buprenorphine"]}],"interventions":[{"name":"Buprenorphine","otherNames":["Naloxone","Suboxone","Buprenex","Subutex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males and females between the ages of 18 to 65, current dependence on prescription opioids as evidenced by documented prior treatment for opioid dependence, signs of opiate withdrawal as evidenced by a Clinical Opiate Withdrawal Scale score of 7 or greater, self-reported history of opioid dependence, and a positive urine toxicology for opiates;\n2. willingness to be detoxified from opioids for buprenorphine maintenance ;\n3. for women of childbearing age, a negative pregnancy test at screening with agreement to use adequate contraception to prevent pregnancy, with monthly pregnancy tests obtained during study participation.\n\nExclusion Criteria:\n\n1. use of heroin for more than 4 days in the past month;\n2. lifetime history of opioid dependence due to heroin alone;\n3. ever used heroin intravenously;\n4. requirement for current ongoing opioid treatment for adequate pain management;\n5. current alcohol, benzodiazepine, barbiturate use with physiologic dependence as determined during screening history and physical,\n6. serious unstable medical illness including bradycardia or other arrhythmias, major cardiovascular, renal, endocrine, or hepatic disorders for which buprenorphine treatment is contraindicated or which at the determination of the MD is medically dangerous;\n7. serious psychiatric illness including psychosis, bipolar disorder with psychosis:\n8. or significant current suicidal or homicidal thoughts necessitating a higher level or care;\n9. known allergy or intolerance to buprenorphine.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Urine Toxicology for Opiate Use","description":"Will be used to document opioid use, a urine toxicology screening will be completed weekly during study participation (12 week study)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Urine Toxicology","description":"Will be used to document cannabinoid use, a urine toxicology screening will be completed weekly during study participation (12 week study)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":5},"commonTop":[]}}}